Acute ischemic stroke
Stroke has a high incidence, with an estimated annual average of 200-250 cases per 100,000 inhabitants. Stroke generally affects people over 55 years and the progressive aging of the population will increase this in the coming decades. The socioeconomic impact of stroke is huge: very high mortality and morbidity (being second cause of death in men and the first in women in developed countries), the most important factor of permanent invalidity, second cause of dementia after Alzheimer's disease, the most common cause of hospital stay, morbidity (disease, hypertension, peripheral arterial disease, diabetes, etc.), the cost of stroke represents 3-4% of the annual budget for European health services.
Currently, the therapeutic approach in stroke patients is limited to artery recanalization using thrombolytic therapy with tissue plasminogen activator (tPA). This treatment improves functional outcome in patients, however it has to be administered before 3.0-4.5 hours after stroke, otherwise adverse effects (hemorrhagic transformation, cerebral damage, etc.) overcome the benefits. As a result, less than 4% of all patients benefit from this therapy. Health stakeholders urge for further research on new therapies for acute stroke accompanying thrombolytic treatment.
Other medical applications
Additionally, the ApTOLL candidate could also be applied to other clinical indications where TLR-4 receptor plays a key role: Multiple Sclerosis, Sepsis or Myocardial Infarction. Taking advantage of the already obtained results and value created, AptaTargets pretends to open new R&D lines to apply the same molecules in those clinical applications.